Daiichi to carve out manufacturing division

Daiichi Pharmaceutical is to set up a new manufacturing subsidiary
in a bid to profit from forthcoming Japanese legislation that makes
it easier for firms to produce drugs for third parties.

The new company, to be made up of its three Japan-based factories, will begin operations from April next year, Daiichi said yesterday, manufacturing drugs such as Cravit, Omnipaque, Panaldine, Artist and Coversyl levofloxacin in bulk form.

The Pharmaceutical Affairs Law, which will take effect in April 2005, has already prompted similar moves to boost contract manufacturing from Taiyo Pharmaceutical Industry, Sumitomo and Kyorin.

The contract manufacturing sector is on a rising trend, with the active pharmaceutical ingredient (API) and intermediates market forecast to grow 7 to 8 per cent annually.

The Daiichi Group,/a> recently implemented a restructuring strategy and the creation of a single unit for its manufacturing activities is expected to reduce costs and improve management efficiency.

Daiichi also plans to integrate Daiichi Technos and Kansai Daiichi Service Co, which service the maintenance of equipment and facilities in its current plants, into the new company, expected to have around 560 employees.

The parent company will continue to take responsibility for the manufacturing division as well as R&D functions related to pharmaceutical manufacturing technologies.

The name and headquarters for the new company are yet to be decided.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars